1036 Active surveillance for low risk prostate cancer: The study protocol of the Movember Global Action Plan 3 (GAP3) project

@article{Bruinsma20151036AS,
  title={1036 Active surveillance for low risk prostate cancer: The study protocol of the Movember Global Action Plan 3 (GAP3) project},
  author={Sophie M Bruinsma and Chris H. Bangma and H. Th. Obbink and Monique J. Roobol},
  journal={European Urology Supplements},
  year={2015},
  volume={14}
}

Topics from this paper

Expert consensus document: Semantics in active surveillance for men with localized prostate cancer — results of a modified Delphi consensus procedure
TLDR
Agreement between international experts has been reached on relevant terms and subsequent definitions regarding AS for patients with localized prostate cancer. Expand
A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
TLDR
Of the criteria used to recommend a switch to active treatment, more than two positive cores and a PSA DT of 0-3 yr were not predictive of unfavorable pathologic outcome on RP, resulting in a substantial group of men discontinued AS without subsequent unfavorable tumor features on RP. Expand
Prostate cancer: Caveat Emptor — long-term outcomes in the Göteborg active surveillance cohort
TLDR
Results from an AS cohort in Sweden suggest that observing men with low-risk and intermediate-risk tumours carries a small — but significant — risk of treatment failure and death from prostate cancer. Expand
The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer
TLDR
This review aims to provide an overview of the improved discovery and evaluation technologies for multiplexed measurement of proteins in bio-fluids and tissues, as well as describe some of the candidate PCa protein biomarkers that have been discovered using them. Expand